Distribution, dosimetry and imaging of [195mPt]cisplatin in cancer patients

Completed

• Conditions: lung cancer; Non-small-cell lung carcinoma; 10027656

• Registration Number: NL-OMON55147
• Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 9 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 6

Inclusion Criteria

- > 18 years of age.
- Diagnosed with NSCLC.
- Planned for concurrent radiotherapy with cisplatin.
- At least one pulmonary tumour lesion of at least 3 cm over the longest axis.

Exclusion Criteria

- Not able to provide informed consent.
- Pregnant or breastfeeding.
- Previous treatment with platinum compounds.
- Claustrophobia.
- eGFR < 60 ml/min.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- Image quality: amongst others tumour-to-background ratio and visual assessment<br /><br>- Dosimetry</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- eGFR<br /><br>- Treatment outcome according to MTB/physician decision. </p><br>